Advertisement

Drugs

, Volume 58, Issue 4, pp 743–760 | Cite as

Orlistat

A Review of its Use in the Management of Obesity
  • Karen M. Hvizdos
  • Anthony Markham
Adis Drug Evaluation

Abstract

Orlistat is a novel non-systemic treatment for obesity. The drug inhibits lipases in the gastrointestinal tract, preventing the absorption of approximately 30% of dietary fat.

Pharmacodynamic and dose-finding studies have established that a 120mg dose of orlistat 3 times daily (with each main meal) is optimal.

Controlled studies have established that orlistat 120mg 3 times daily for 1 year, in conjunction with a hypocaloric diet, enables weight reduction of 7.9 to 10.2% in obese non-diabetic individuals. In 1 study the reduction was 6.2% in obese patients with type 2 diabetes. Orlistat 120mg 3 times daily was significantly more effective than placebo (also given in conjunction with a hypocaloric diet) in these studies. The drug was also significantly more effective than placebo in 2-year randomised double-blind studies involving >2000 patients. During the second year of treatment, when patients were switched from a hypocaloric diet to a eucaloric diet, orlistat recipients regained significantly less weight than placebo recipients.

Orlistat appears to improve lipid profiles in non-diabetic obese patients, reducing levels of total cholesterol and low density lipoprotein cholesterol. In a study of patients with obesity associated with type 2 diabetes, patients treated with orlistat lost more weight and had improved serum lipid profiles compared with placebo recipients. In addition, orlistat-treated patients achieved significant improvements in glycaemic control, enabling dosages of antidiabetic drugs to be reduced.

Long term (1 to 2 years) tolerability data from 2038 patients in placebo-controlled trials revealed that the drug was generally well tolerated. The most commonly reported adverse events were related to decreased fat absorption and included oily faecal spotting, flatus with discharge, faecal urgency and oily stool. Systemic adverse events attributable to orlistat were negligible.

Conclusion: Orlistat in conjunction with a hypocaloric diet has been shown to induce clinically significant weight loss in keeping with current guidelines for the management of obesity. This, together with its acceptable tolerability profile and lack of systemic adverse events, make it an attractive option in the treatment of obesity. The drug may have a positive effect on obesity-associated cardiovascular risk factors and type 2 diabetes.

Keywords

Adis International Limited Placebo Recipient Orlistat Sibutramine Hypocaloric Diet 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Drent ML, van der Veen E A. First clinical studies with orlistat: a short review. Obes Res 1995 Nov; 3 Suppl. 4: 623S–5SPubMedGoogle Scholar
  2. 2.
    Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro-18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992 Jan; 55 Suppl.: 309S–13SPubMedGoogle Scholar
  3. 3.
    Hadváry P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 1988 Dec 1; 256: 357–61PubMedGoogle Scholar
  4. 4.
    Borgström B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 1988 Oct 14; 962: 308–16PubMedCrossRefGoogle Scholar
  5. 5.
    Güzelhan G, Odink J, Jansen-Zuidema JJ, et al. Influence of dietary composition on the inhibition of fat absorption by orlistat. J Int Med Res 1994 Sep–Oct; 22: 255–65PubMedGoogle Scholar
  6. 6.
    Hartmann D, Hussain Y, Güzelhan C, et al. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. Br J Clin Pharmacol 1993 Sep; 36: 266–70PubMedCrossRefGoogle Scholar
  7. 7.
    Froehlich F, Hartmann D, Guezelhan C, et al. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Dig Dis Sci 1996 Dec; 41: 2404–8PubMedCrossRefGoogle Scholar
  8. 8.
    Drent ML, Popp-Snijders C, Adèr HJ, et al. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects. Obes Res 1995 Nov; 3: 573–81PubMedGoogle Scholar
  9. 9.
    Degen L, Matzinger D, Maecke H, et al. Influence of orlistat on gastric emptying rates of fats and solids in healthy subjects [abstract]. Gastroenterology 1998 Apr 15; 114 (Pt 2 Suppl.): 740CrossRefGoogle Scholar
  10. 10.
    Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999 Jan; 39: 41–6PubMedCrossRefGoogle Scholar
  11. 11.
    Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995 Nov; 35: 1103–8PubMedGoogle Scholar
  12. 12.
    Roche Laboratories. Xenical® (orlistat) Product information. Nutley (NJ), 1999Google Scholar
  13. 13.
    Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21 Suppl. 3:S12–23Google Scholar
  14. 14.
    Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996; 36(11): 1006–11PubMedCrossRefGoogle Scholar
  15. 15.
    Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998 Apr; 54: 125–32PubMedCrossRefGoogle Scholar
  16. 16.
    Weibel EK, Hadvary P, Hochuli E, et al. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J Antibiot Tokyo 1987 Aug; 40: 1081–5PubMedCrossRefGoogle Scholar
  17. 17.
    Zhi J, Melia AT, Guerciolini R, et al. The effect of tetrahydrolipstatin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 659–66PubMedGoogle Scholar
  18. 18.
    Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995 May; 35: 521–5PubMedGoogle Scholar
  19. 19.
    Oo CY, Akbari B, Lee S. Effect of orlistat, a novel anti-obesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia. Clin Drug Invest 1999 Mar; 17: 217–23CrossRefGoogle Scholar
  20. 20.
    Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995 Aug; 35: 840–3PubMedGoogle Scholar
  21. 21.
    Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL®) in healthy volunteers. J Clin Pharmacol 1996 Apr; 36: 352–5PubMedGoogle Scholar
  22. 22.
    Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 654–8PubMedGoogle Scholar
  23. 23.
    Hartmann D, Güzelhan C, Zuiderwijk PBM. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996 Jul; 50: 421–4PubMedCrossRefGoogle Scholar
  24. 24.
    Weber C, Tam YK, Schmidtke-Schrezenmeier G. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996 Sep; 51: 87–90PubMedCrossRefGoogle Scholar
  25. 25.
    Melia AT, Zhi J, Zelasko R, et al. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol 1998 Nov–Dec; 54: 773–7PubMedCrossRefGoogle Scholar
  26. 26.
    Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers. J Clin Pharmacol 1996 Feb; 36: 152–9PubMedGoogle Scholar
  27. 27.
    Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 647–53PubMedGoogle Scholar
  28. 28.
    Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998 Aug; 21: 1288–94PubMedCrossRefGoogle Scholar
  29. 29.
    Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999 Jan 20; 281: 235–42PubMedCrossRefGoogle Scholar
  30. 30.
    Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998 Jul 18; 352: 167–72PubMedCrossRefGoogle Scholar
  31. 31.
    Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999 June; 69: 1108–16PubMedGoogle Scholar
  32. 32.
    Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomised, double-blind, placebo-controlled, multicentre study of orlistat (Xenical®), a gastrointestinal lipase inhibitor. Int J Obes (In press)Google Scholar
  33. 33.
    Noack R. Two-year study of orlistat in the treatment of obesity [abstract]. 79th Annual Meeting of the American Endocrine Society: 1997 Jun 11–14; MinneapolisGoogle Scholar
  34. 34.
    Hauptman J, Lucas C, Boldrin M, et al. Orlistat, a gastrointestinal lipase inhibitor, in the long-term treatment of obesity in a primary care setting. Arch Fam Med (In press)Google Scholar
  35. 35.
    Drent ML, Larsson I, William-Olsson T, et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995 Apr; 19: 221–6Google Scholar
  36. 36.
    Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes 1993; 17: 241–4Google Scholar
  37. 37.
    Rössner S, Sjöström L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res (In press)Google Scholar
  38. 38.
    Rissanen A, Sjöström L, Rössner S. Early weight loss with orlistat as a predictor of long-term success in obesity treatment [abstract no. 577]. Int J Obes 1999; 23 Suppl. 5: S174CrossRefGoogle Scholar
  39. 39.
    Stolshek B, Mathias S, Pasta D, et al. Health-related quality of life (HRQoL) during treatment with orlistat (Xenical®) [abstract no. 518]. Int J Obes 1999 May; 23 Suppl. 5: S158Google Scholar
  40. 40.
    Scheen AJ, Lefébvre PJ. Pharmacological treatment of obesity: present status. Int J Obes 1999 Feb; 23 Suppl. 1: 47–53CrossRefGoogle Scholar
  41. 41.
    Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46(5): 405–10PubMedCrossRefGoogle Scholar
  42. 42.
    Rissanen A. Orlistat-induced weight loss improves response to oral glucose tolerance testing [abstract no. P677]. Int J Obes 1998 Aug; 22 Suppl. 3: S274Google Scholar
  43. 43.
    Watkins PJ, Joint Working Party of the British Diabetic Association, the Research Unit of the Royal College of Physicians, and the Royal College of General Practitioners. Guidelines for good practice in the diagnosis and treatment of non-insulin-dependent diabetes mellitus. J R Coll Physicians Lond 1993 Jul; 27(3): 259–66Google Scholar
  44. 44.
    Pataky Z, Golay A. Effect of treatment with orlistat for one-year on blood pressure in obese patients [abstract no. 582]. Int J Obes 1999; 23 Suppl. 5: S175Google Scholar
  45. 45.
    Lucas C, Hauptman J, Boldrin M, et al. Effect of orlistat on weight loss and cardiovascular disease risk factors in obese hypertensive patients. Hoffman-La Roche, Nutley (NJ), 1999. (Data on file)Google Scholar
  46. 46.
    Canovatchel W. Long-term tolerability profile of orlistat, an intestinal lipase inhibitor [abstract no. 769]. Diabetologia 1997 Jun; 40 Suppl. 1: A196Google Scholar
  47. 47.
    Roche Laboratories. Expert report on additional breast cancer information for Xenical® (orlistat). Roche Laboratories (New Jersey). 1999, (Data on file)Google Scholar
  48. 48.
    Roche Products Ltd. Xenical® (orlistat) Product information. Hertfordshire, UK, 1998Google Scholar
  49. 49.
    Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995 Sep 14; 333: 677–85PubMedCrossRefGoogle Scholar
  50. 50.
    Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes 1998 Jan; 22(1): 39–47CrossRefGoogle Scholar
  51. 51.
    Seidell JC. The burden of obesity and its sequelae. Dis Manage Health Outcomes 1999 Jan; 5: 13–21CrossRefGoogle Scholar
  52. 52.
    Lean MEJ, Han TS, Seidell JC. Impairment of health and quality of life in people with large waist circumference. Lancet 1998 Mar 21; 351: 853–6PubMedCrossRefGoogle Scholar
  53. 53.
    Han TS, Richmond P, Avenell A, et al. Waist circumference reduction and cardiovascular benefits during weight loss in women. Int J Obes 1997; 21: 127–34CrossRefGoogle Scholar
  54. 54.
    Expert Panel on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998 Sep 28; 158: 1855–67CrossRefGoogle Scholar
  55. 55.
    Pi-Sunyer X. Guidelines for the approval and use of drugs to treat obesity — a position paper of the North American Association for the Study of Obesity. Obes Res 1995 Sep; 3: 473–8Google Scholar
  56. 56.
    Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. Arch Intern Med 1997; 157: 657–67CrossRefGoogle Scholar
  57. 57.
    Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999 Aug 5; 341(6): 427–34PubMedCrossRefGoogle Scholar
  58. 58.
    Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines: do the recent market removals mean there is a problem? JAMA 1999; 281: 1728–34PubMedCrossRefGoogle Scholar
  59. 59.
    Goldenberg MM, Caspi A. Orlistat: a novel concept in the treatment of obesity. PT 1998 Nov; 23: 571–80Google Scholar
  60. 60.
    McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998 Dec; 56: 1093–124PubMedCrossRefGoogle Scholar
  61. 61.
    Jones SP, Smith IG, Kelly F, et al. Long-term weight loss with sibutramine [abstract]. Int J Obes 1995; 19 Suppl. 2: 41Google Scholar
  62. 62.
    Knoll Pharmaceutical Company. Meridia® (sibutramine hydrochloride monohydrate) Product information. Mount Olive (NJ), 1997Google Scholar
  63. 63.
    Garrow J. Flushing away the fat. BMJ 1998 Sep 26; 317: 830–1PubMedCrossRefGoogle Scholar
  64. 64.
    McCarthy WJ. Orlistat and weight loss [letter]. Lancet 1998 Oct 31; 352: 1473PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand

Personalised recommendations